Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
Recruiting
Observational Study
B-cell Non Hodgkin Lymphoma
Relapse
Refractory Lymphoma
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 96 (estimated)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients who received glofitamab according to Compassionate Use Program AG42296
2. Age \> 18 years
3. Patients who received at least one dose of glofitamab between March 2022 and September 2023 in the context of the compassionate use program and who completed at least 1 year …
Contacts